Blog Buzz: July 16 – July 20

Posted on by

Open access announcements, the gene patent debate, and an ORCID rollout date, OH MY!

It was a big week for open access announcements. The UK announced a plan for open access of all publicly funded research in two years on Monday. (In a post on her blog, Maria Pretzler asks who will pay.) Following hot on their heels, the European Commission released recommendations for member states on access to and preservation of publicly funded scientific research Tuesday. The New Scientist also covered the topic.

According to the NY Times, gene therapy is nearing regulatory approval in Europe.

The Daily Scan reports on James Watson’s amicus brief in the ACLU-Myriad gene patenting case. Nature News has a piece on how the case could affect personalized medicine.

The ORCID (Open Researcher and Contributor ID) registry, the goal of which is to “solve the long-standing name ambiguity problem in scholarly communication” has announced it will go live this October!

2011 Journal Citation Report is Now Available

Posted on by

Journal Citation Reports 2010 Thomson Reuters has recently released the 2011 Journal Citation Reports (JCR).  JCR is an annual publication analyzing one year of citation data. It provides a variety of impact and influence metrics, including the Journal Impact Factor and Eigenfactor from the Thomson Reuters citation indexes.

The 2010 JCR features the largest-ever JCR with 10,677 journal listings in 232 disciplines; 2,552 publishers from 82 countries are represented. A total of 528 journals receive their first Journal Impact Factor in this latest JCR release.

You can access the 2011 Journal Citation Reports from here, or through the MSKsearch search box from the Library’s Website. For more information on Journal Citation Reports, please visit here.

MSKCC in the News: June 28 – July 27

Posted on by
  • Computerworld reports that Stephen Chou, a Princeton engineering professor, is working with researchers at MSKCC to use nanotechnology to develop tests to detect diseases, like cancer and Alzheimer’s disease.
  • A study authored by MSKCC doctors published in the Journal of the American College of Surgeons confirmed that their early analysis of the NanoKnife® System demonstrated safety for treating liver malignancies adjacent to blood vessels, potentially expanding therapeutic options for physicians in previously challenging areas.